| Home | E-Submission | Sitemap | Contact Us |  
J Korean Soc Ther Radiol Oncol > Volume 18(4); 2000 > Article
The Journal of the Korean Society for Therapeutic Radiology and Oncology 2000;18(4): 337-344.
Enhancement of Tumor Radioresponse by Combined Chemotherapy in Murine Hepatocarcinoma
Jinsil Seong, Sung Hee Kim, Chang Ok Suh
Department of Radiation Oncology, Yonsei University Medical College, Yonsei Cancer Center.
BACKGROUNDS: The purpose of this study was to identify drugs that can enhance radioresponse of murine hepatocarcinoma.
C3H/HeJ mice bearing 8 mm tumors of murine hepatocarcinoma, HCa-I, were treated with 25 Gy radiation and one of the following drugs: 5-Fu, 150 mg/kg; adriamycin, 8 mg/kg; cisplatin, 6 mg/kg; paclitaxel, 40 mg/kg; and gemcitabine, 50 mg/kg. Tumor response to the treatment was determined by tumor growth delay assay and by enhancement factor. Apoptotic level was assessed in tissue sections. Expression of regulating molecules was analyzed by western blotting for p53, Bcl-2, Bax, Bcl-XL, Bcl-XS, and p21WAF1/CIP1.
Among the drugs tested, only gemcitabine enhanced the antitumor effect of radiation, with enhancement factor of 1.6. Induction of apoptosis by a combination of gemcitabine and radiation was shown as only additive level. In analysis of radiation-induced expression of regulating molecules, the most significant change by combining gemcitabine was activation of p21WAF1/CIP1.
Gemcitabine is the first drug showing an enhancement of radioresponse in murine hepatocarcinoma, when combined with radiation. The key element of enhancement is thought to be p21WAF1/CIP1.
Key Words: Hepatocarcinoma, Gemcitabine, Radiation, Apoptosis, p21WAF1/CIP1
Editorial Office
Department of Radiation Oncology, Samsung Medical Center,
Proton Therapy Center, B2, 81, Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea
Tel : +82-2-3410-3617
E-mail: rojeditor@gmail.com, roj@kosro.or.kr
Copyright © The Korean Society for Radiation Oncology.                      Developed in M2PI
Close layer
prev next